Manuel Gardea-ResendezMonica J. Taylor-DesirFrancisco Romo-NavaDavid BondEric J. VallenderAlfredo B. Cuellar-BarbozaMiguel L. PrietoNicolas NunezMarin VeldicAysegul Ozerdem2026-03-222026-03-22202210.1097/jcp.0000000000001532https://doi.org/10.1097/jcp.0000000000001532https://andeanlibrary.org/handle/123456789/58184Citaciones: 1This study confirms previously identified TD risk factors, such as age, sex, and bipolar subtype in a large BD cohort. Limitations included a cross-sectional design and the lack of tardive illness severity assessment. As atypical antipsychotics continue to be primary mood stabilization treatment, attempting to harmonize large data sets to identify additional biomarkers of tardive risk will optimize individualized care for patients with BD.enTardive dyskinesiaBipolar disorderMedicineMood stabilizerMoodPsychiatryBipolar illnessPhenotypeBioinformaticsTreatment of bipolar disorderarticle